Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...

Days ahead of its contentious annual shareholders’ meeting slated for Sept. 19, Masimo Corp. established partnerships with two big players – Google LLC and Qualcomm Technologies Inc. – to ...

Metastatic solid tumors may be curable now. Among the most profound results presented over the weekend at the European ...

Biolexis Therapeutics Inc. has announced findings from a study of its oral small-molecule GLP-1 agonist, BLX-7006, in a ...

The first patenting from Encephalogix Inc. details its development of platform that uses machine learning and AI to analyze ...

Researchers from Janssen Research & Development LLC presented preclinical data for JNJ-75220795 (ARO-PNPLA3), a ...

After capturing the North American market with Wegovy (semaglutide) and Zepbound (tirzepatide), Novo Nordisk A/S and Eli Lilly and Co. are advancing blockbuster glucagon-like peptide-1 (GLP-1) ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

The U.S. FDA approved Apple Inc.’s Airpods Pro 2 as an over-the-counter assistive hearing device for adults with ...

More than three months ago, investors first learned that ivonescimab, a PD-1/VEGF-targeting bispecific antibody from Summit ...

Incretins are not just metabolic hormones that regulate glucose levels after eating. Their functions go beyond stimulating ...

Brightflow SAS raised €16.5 million (US$18 million) in a series A financing round that will go towards developing its right ...